Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Snake Bite
Interventions: Crotalinae (pit viper) equine immune F(ab)2, Crotalidae Polyvalent Immune Fab, ovine; Biological
Lead sponsor: Instituto Bioclon S.A. de C.V.; Industry
Eligibility: 2 Years to 80 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Loma Linda, California + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Methotrexate, Abatacept placebo, Methotrexate placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Hot Springs, Arkansas • Sarasota, Florida + 12 more

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: Darolutamide (BAY1841788, Nubeqa), ADT; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 31
States / cities: Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Healthy Volunteers
Interventions: Zucapsaicin, Placebo patch; Drug
Lead sponsor: Winston Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Port Chester, New York

Conditions: Diabetic Macular Edema
Interventions: bevasiranib; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Beechwood, Ohio

Conditions: Asthma
Interventions: Montelukast, Sugar pill; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Post Traumatic Stress Disorder
Interventions: Modius Spero active device, Sham device; Device
Lead sponsor: Neurovalens Ltd.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
Interventions: Not listed
Lead sponsor: Miltenyi Biomedicine GmbH; Industry
Eligibility: 1 Year to 66 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Oral Malodor (Halitosis)
Interventions: Sodium Fluoride Dentifrice, Stannous Fluoride Toothpaste (SnF); Drug
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Pregnancy in Adolescence, Sexually Transmitted Diseases
Interventions: Wrap It Up (WIU); Behavioral
Lead sponsor: ETR Associates; Other
Eligibility: 16 Years to 19 Years
Enrollment: 1,120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Scotts Valley, California

Conditions: Pain, Postoperative, Pelvic Organ Prolapse
Interventions: Ice T, Motrin/Percocet/Dilaudid for breakthrough; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Adverse Childhood Experiences
Interventions: Three-Tier Model; Behavioral
Lead sponsor: Loma Linda University; Other
Eligibility: 3 Years to 11 Years
Enrollment: 340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 844 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Universal Behavioral Supports, Teacher Training
Interventions: Multi-Tiered Systems of Support for Teacher Training; Behavioral
Lead sponsor: Western Kentucky University; Other
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bowling Green, Kentucky

Conditions: Prostatectomy, Nephrectomy, Laparoscopy, Robotics
Interventions: Teleflex HemoLock clip, Aesculap U-clip; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HNSCC
Interventions: Danvatirsen, Pembrolizumab; Drug
Lead sponsor: Flamingo Therapeutics NV; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 21
States / cities: Tucson, Arizona • Irvine, California • Torrance, California + 17 more

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Maitland, Florida

Conditions: Sleep Initiation and Maintenance Disorders, Pregnancy
Interventions: No Intervention; Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 16 Years to 49 Years · Female only
Enrollment: 861 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: Plaque Psoriasis
Interventions: 188-0551 Spray, Vehicle Spray; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more

Conditions: Diabetes Mellitus II
Interventions: Muraglitazar; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 149
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 146 more

Conditions: Arthritis, Rheumatoid
Interventions: CP-690,550, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 33
States / cities: Gilbert, Arizona • Hot Springs, Arkansas • Upland, California + 26 more

Conditions: Narcolepsy
Interventions: SUVN-G3031, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more

Conditions: Differentiated Thyroid Cancer
Interventions: Cabozantinib, Placebo; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 16 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 31
States / cities: Newport Beach, California • Sacramento, California • San Francisco, California + 27 more

Conditions: Fecal Incontinence, Neurogenic Bowel
Interventions: Dose Response - NS and USP Glycerin - First Intervention, Effectiveness - NS and USP Glycerin - Second Intervention; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 3 Years to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.

Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Civamide Patch Safety, Tolerability and PK Study

Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema

Moderate to Persistent Asthma in the Obese Subject

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for PTSD

PRAISE-IR Versus CIBMTR Controls

Evaluation of a Stannous Fluoride Dentifrice for Control of Oral Malodor

Wrap It Up Rigorous Evaluation

Ice T Postoperative Multimodal Pain Regimen in FPMRS Surgery

Building Resilient Families

A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

Multi-Tiered Systems of Support for Teacher Training in Classroom Management

Comparison Study of Two Different Surgical Clips During Laparoscopic Urologic Surgery

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

Dose Ranging Study With LT, Monotherapy, PPAR

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children